What one share of Zenas BioPharma holds
We are a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. With the evolving understanding
Zenas BioPharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$9.07 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$4.23 |
| Cash and investments | $3.10 |
| Debt | $3.52 |
| Book value | $3.90 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $32.65 | −$24.25 | $0.01 | −$19.95 | — | −$143.15 |
| 2024 | $0.38 | −$11.89 | $0.01 | −$9.08 | — | — |
| 2025 | $0.22 | −$8.44 | $0.00 | −$3.85 | — | $4.44 |
Common questions about Zenas BioPharma
How much does one share of Zenas BioPharma earn?
Over the last 12 months, Zenas BioPharma lost $9.07 for each share on $0.02 of sales.
Does Zenas BioPharma pay a dividend?
Zenas BioPharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Zenas BioPharma’s book value per share?
Zenas BioPharma’s book value is $3.90 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Zenas BioPharma have?
Each share of Zenas BioPharma has $3.10 of cash and investments and $3.52 of debt, as of June 30, 2026.
What is Zenas BioPharma’s free cash flow per share?
−$4.23 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.